1
|
Ye T, Yu Y, Qu G, Ma H, Shi S, Ji J, Lyu J, Yang Y, Liu N, Li F. 211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma. Eur J Med Chem 2024; 279:116919. [PMID: 39342682 DOI: 10.1016/j.ejmech.2024.116919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Revised: 09/20/2024] [Accepted: 09/25/2024] [Indexed: 10/01/2024]
Abstract
Fibroblast activation protein-α (FAPα) is highly expressed in tumor-associated cells and has become one of the most attractive targeting sites in cancer diagnosis and therapy. To ameliorate the rapid metabolism of FAPα inhibitor (FAPI), here, a multifunctional binding agent was introduced to simultaneously achieve 211At radiolabeling and tumor retention prolongation of corresponding radiolabeled drug. 211At-APBA-FAPI was successfully synthesized by conjugating 211At with the designed FAPI carrier in satisfactory radiochemical yield (>60 %). 211At-APBA-FAPI exhibited excellent in vitro stability, significant tumor affinity and specific killing effect on FAPα-positive U87MG cells. Molecular docking reveals that FAPI decorated with albumin binder can bind with FAPα protein via multiple intermolecular interactions with a considerable binding energy of -9.66 kcal/mol 211At-APBA-FAPI exhibits good targeting in murine xenograft models, showing obviously longer tumor retention than previously-reported radioastatinated compound. As a result, 211At-APBA-FAPI presents pronounced therapeutic effect with ignorable normal organs/tissues biotoxicity. All these indicate that introducing a multifunctional binding agent can effectively enhance the availability of FAPI for 211At conjugation and tumoricidal effect, providing vital hints for the translation of targeted-alpha therapy based on radiolabeled FAPI derivatives.
Collapse
Affiliation(s)
- Tianzhen Ye
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Yuying Yu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Guofeng Qu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Huan Ma
- Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China
| | - Shilong Shi
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Jiujian Ji
- West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Jie Lyu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Yuanyou Yang
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Ning Liu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China
| | - Feize Li
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, China.
| |
Collapse
|
2
|
Watabe T, Kaneda-Nakashima K, Kadonaga Y, Ooe K, Sampunta T, Hirose N, Yin X, Haba H, Kon Y, Toyoshima A, Cardinale J, Giesel FL, Fukase K, Tomiyama N, Shirakami Y. Preclinical Evaluation of Biodistribution and Toxicity of [ 211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer. Int J Mol Sci 2024; 25:5667. [PMID: 38891856 PMCID: PMC11172375 DOI: 10.3390/ijms25115667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Revised: 05/15/2024] [Accepted: 05/20/2024] [Indexed: 06/21/2024] Open
Abstract
Astatine (211At) is a cyclotron-produced alpha emitter with a physical half-life of 7.2 h. In our previous study, the 211At-labeled prostate-specific membrane antigen (PSMA) compound ([211At]PSMA-5) exhibited excellent tumor growth suppression in a xenograft model. We conducted preclinical biodistribution and toxicity studies for the first-in-human clinical trial. [211At]PSMA-5 was administered to both normal male ICR mice (n = 85) and cynomolgus monkeys (n = 2). The mice were divided into four groups for the toxicity study: 5 MBq/kg, 12 MBq/kg, 35 MBq/kg, and vehicle control, with follow-ups at 1 day (n = 10 per group) and 14 days (n = 5 per group). Monkeys were observed 24 h post-administration of [211At]PSMA-5 (9 MBq/kg). Blood tests and histopathological examinations were performed at the end of the observation period. Blood tests in mice indicated no significant myelosuppression or renal dysfunction. However, the monkeys displayed mild leukopenia 24 h post-administration. Despite the high accumulation in the kidneys and thyroid, histological analysis revealed no abnormalities. On day 1, dose-dependent single-cell necrosis/apoptosis was observed in the salivary glands of mice and intestinal tracts of both mice and monkeys. Additionally, tingible body macrophages in the spleen and lymph nodes indicated phagocytosis of apoptotic B lymphocytes. Cortical lymphopenia (2/10) in the thymus and a decrease in the bone marrow cells (9/10) were observed in the 35 MBq/kg group in mice. These changes were transient, with no irreversible toxicity observed in mice 14 days post-administration. This study identified no severe toxicities associated with [211At]PSMA-5, highlighting its potential as a next-generation targeted alpha therapy for prostate cancer. The sustainable production of 211At using a cyclotron supports its applicability for clinical use.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Radiology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka 560-0043, Japan
| | - Yuichiro Kadonaga
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | - Thosapol Sampunta
- Department of Radiology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
| | - Naoki Hirose
- Institute of Experimental Animal Sciences, Faculty of Medicine, Osaka University, Osaka 565-0871, Japan
| | - Xiaojie Yin
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Yukiyoshi Kon
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | - Jens Cardinale
- Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany
| | - Frederik L. Giesel
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
- Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany
| | - Koichi Fukase
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Osaka 560-0043, Japan
| | - Noriyuki Tomiyama
- Department of Radiology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan
| | | |
Collapse
|
3
|
Naka S, Ooe K, Shirakami Y, Kurimoto K, Sakai T, Takahashi K, Toyoshima A, Wang Y, Haba H, Kato H, Tomiyama N, Watabe T. Production of [ 211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI Radiopharm Chem 2024; 9:29. [PMID: 38619655 PMCID: PMC11018728 DOI: 10.1186/s41181-024-00257-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 03/21/2024] [Indexed: 04/16/2024] Open
Abstract
BACKGROUND The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I). Herein, we aimed to establish a robust method for the manufacturing and quality control of [211At]NaAt solution for intravenous administration under the good manufacturing practice guidelines for investigational products to conduct an investigator-initiated clinical trial. RESULTS 211At was separated and purified via dry distillation using irradiated Bi plates containing 211At obtained by the nuclear reaction of 209Bi(4He, 2n)211At. After purification, the 211At trapped in the cold trap was collected in a reaction vessel using 15 mL recovery solution (1% ascorbic acid and 2.3% sodium hydrogen carbonate). After stirring the 211At solution for 1 h inside a closed system, the reaction solution was passed through a sterile 0.22 μm filter placed in a Grade A controlled area and collected in a product vial to prepare the [211At]NaAt solution. According to the 3-lot tests, decay collected radioactivity and radiochemical yield of [211At]NaAt were 78.8 ± 6.0 MBq and 40 ± 3%, respectively. The radiochemical purity of [211At]At- obtained via ion-pair chromatography at the end of synthesis (EOS) was 97 ± 1%, and remained > 96% 6 h after EOS; it was detected at a retention time (RT) 3.2-3.3 min + RT of I-. LC-MS analysis indicated that this principal peak corresponded with an astatide ion (m/z = 210.988046). In gamma-ray spectrometry, the 211At-related peaks were identified (X-ray: 76.9, 79.3, 89.3, 89.8, and 92.3 keV; γ-ray: 569.7 and 687.0 keV), whereas the peak at 245.31 keV derived from 210At was not detected during the 22 h continuous measurement. The target material, Bi, was below the 9 ng/mL detection limit in all lots of the finished product. The pH of the [211At]NaAt solution was 7.9-8.6; the concentration of ascorbic acid was 9-10 mg/mL. Other quality control tests, including endotoxin and sterility tests, confirmed that the [211At]NaAt solution met all quality standards. CONCLUSIONS We successfully established a stable method of [211At]NaAt solution that can be administered to humans intravenously as an investigational product.
Collapse
Affiliation(s)
- Sadahiro Naka
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Pharmacy, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yoshifumi Shirakami
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kenta Kurimoto
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Pharmacy, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Toshihiro Sakai
- Hanwa Intelligent Medical Center, Hanwa Daini Senboku Hospital, 3176 Fukaikitamachi, Naka- ku, Sakai, Osaka, 599-8271, Japan
| | - Kazuhiro Takahashi
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Hiroki Kato
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Noriyuki Tomiyama
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Radiology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
4
|
Burgers PC, Zeneyedpour L, Luider TM, Holmes JL. Estimation of thermodynamic and physicochemical properties of the alkali astatides: On the bond strength of molecular astatine (At 2 ) and the hydration enthalpy of astatide (At - ). JOURNAL OF MASS SPECTROMETRY : JMS 2024; 59:e5010. [PMID: 38488842 DOI: 10.1002/jms.5010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 01/29/2024] [Accepted: 02/01/2024] [Indexed: 03/17/2024]
Abstract
The recent accurate and precise determination of the electron affinity (EA) of the astatine atom At0 warrants a re-investigation of the estimated thermodynamic properties of At0 and astatine containing molecules as this EA was found to be much lower (by 0.4 eV) than previous estimated values. In this contribution we estimate, from available data sources, the following thermodynamic and physicochemical properties of the alkali astatides (MAt, M = Li, Na, K, Rb, Cs): their solid and gaseous heats of formation, lattice and gas-phase binding enthalpies, sublimation energies and melting temperatures. Gas-phase charge-transfer dissociation energies for the alkali astatides (the energy requirement for M+ At- ➔ M0 + At0 ) have been obtained and are compared with those for the other alkali halides. Use of Born-Haber cycles together with the new AE (At0 ) value allows the re-evaluation of ΔHf (At0 )g (=56 ± 5 kJ/mol); it is concluded that (At2 )g is a weakly bonded species (bond strength <50 kJ/mol), significantly weaker bonded than previously estimated (116 kJ/mol) and much weaker bonded than I2 (148 kJ/mol), but in agreement with the finding from theory that spin-orbit coupling considerably reduces the bond strength in At2 . The hydration enthalpy (ΔHaq ) of At- is estimated to be -230 ± 2 kJ/mol (using ΔHaq [H+ ] = -1150.1 kJ/mol), in good agreement with molecular dynamics calculations. Arguments are presented that the largest alkali halide, CsAt, like the smallest, LiF, will be only sparingly soluble in water, following the generalization from hard/soft acid/base principles that "small likes small" and "large likes large."
Collapse
Affiliation(s)
- Peter C Burgers
- Department of Neurology, Laboratory of Neuro-Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Lona Zeneyedpour
- Department of Neurology, Laboratory of Neuro-Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Theo M Luider
- Department of Neurology, Laboratory of Neuro-Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - John L Holmes
- Department of Chemistry and Biological Sciences, University of Ottawa, Ottawa, Canada
| |
Collapse
|
5
|
Liatsou I, Josefsson A, Yu J, Li Z, Davis K, Brayton C, Wang H, Hobbs RF, Sgouros G. Early Normal Tissue Effects and Bone Marrow Relative Biological Effectiveness for an Actinium 225-Labeled HER2/neu-Targeting Antibody. Int J Radiat Oncol Biol Phys 2023; 117:1028-1037. [PMID: 37331568 DOI: 10.1016/j.ijrobp.2023.06.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 05/16/2023] [Accepted: 06/11/2023] [Indexed: 06/20/2023]
Abstract
PURPOSE In this study we determined the dose-independent relative biological effectiveness (RBE2) of bone marrow for an anti-HER2/neu antibody labeled with the alpha-particle emitter actinium 225 (225Ac). Hematologic toxicity is often a consequence of radiopharmaceutical therapy (RPT) administration, and dosimetric guidance to the bone marrow is required to limit toxicity. METHODS AND MATERIALS Female neu/N transgenic mice (MMTV-neu) were intravenously injected with 0 to 16.65 kBq of the alpha-particle emitter labeled antibody, 225Ac-DOTA-7.16.4, and euthanized at 1 to 9 days after treatment. Complete blood counts were performed. Femurs and tibias were collected, and bone marrow was isolated from 1 femur and tibia and counted for radioactivity. Contralateral intact femurs were fixed, decalcified, and assessed by histology. Marrow cellularity was the biologic endpoint selected for RBE2 determination. For the reference radiation, both femurs of the mice were photon irradiated with 0 to 5 Gy using a small animal radiation research platform. RESULTS Response as measured by cellularity for the alpha-particle emitter RPT (αRPT) RPT and the external beam radiation therapy were linear and linear quadratic, respectively, as a function of absorbed dose. The resulting dose-independent RBE2 for bone marrow was 6. CONCLUSIONS As αRPT gains prominence, preclinical studies evaluating RBE in vivo will be important in relating to human experience with beta-particle emitter RPT. Such normal tissue RBE evaluations will help mitigate unexpected toxicity in αRPT.
Collapse
Affiliation(s)
- Ioanna Liatsou
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
| | - Anders Josefsson
- Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Jing Yu
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Zhi Li
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Kaori Davis
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Cory Brayton
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Hao Wang
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Robert F Hobbs
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - George Sgouros
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
6
|
Albertsson P, Bäck T, Bergmark K, Hallqvist A, Johansson M, Aneheim E, Lindegren S, Timperanza C, Smerud K, Palm S. Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front Med (Lausanne) 2023; 9:1076210. [PMID: 36687417 PMCID: PMC9859440 DOI: 10.3389/fmed.2022.1076210] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 12/06/2022] [Indexed: 01/09/2023] Open
Abstract
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Collapse
Affiliation(s)
- Per Albertsson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,*Correspondence: Per Albertsson ✉
| | - Tom Bäck
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Karin Bergmark
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Andreas Hallqvist
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Mia Johansson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Emma Aneheim
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden,Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Sture Lindegren
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Chiara Timperanza
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Knut Smerud
- Smerud Medical Research International AS, Oslo, Norway
| | - Stig Palm
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
7
|
Takashima H, Ohnuki K, Manabe S, Koga Y, Tsumura R, Anzai T, Wang Y, Yin X, Sato N, Shigekawa Y, Nambu A, Usuda S, Haba H, Fujii H, Yasunaga M. Tumor Targeting of 211At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Mol Pharm 2022; 20:1156-1167. [PMID: 36573995 PMCID: PMC9906747 DOI: 10.1021/acs.molpharmaceut.2c00869] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Astatine-211 (211At) is an alpha emitter applicable to radioimmunotherapy (RIT), a cancer treatment that utilizes radioactive antibodies to target tumors. In the preparation of 211At-labeled monoclonal antibodies (211At-mAbs), the possibility of radionuclide-induced antibody denaturation (radiolysis) is of concern. Our previous study showed that this 211At-induced radiochemical reaction disrupts the cellular binding activity of an astatinated mAb, resulting in attenuation of in vivo antitumor effects, whereas sodium ascorbate (SA), a free radical scavenger, prevents antibody denaturation, contributing to the maintenance of binding and antitumor activity. However, the influence of antibody denaturation on the pharmacokinetics of 211At-mAbs relating to tumor accumulation, blood circulation time, and distribution to normal organs remains unclear. In this study, we use a radioactive anti-human epidermal growth factor receptor 2 (anti-HER2) mAb to demonstrate that an 211At-induced radiochemical reaction disrupts active targeting via an antigen-antibody interaction, whereas SA helps to maintain targeting. In contrast, there was no difference in blood circulation time as well as distribution to normal organs between the stabilized and denatured immunoconjugates, indicating that antibody denaturation may not affect tumor accumulation via passive targeting based on the enhanced permeability and retention effect. In a high-HER2-expressing xenograft model treated with 1 MBq of 211At-anti-HER2 mAbs, SA-dependent maintenance of active targeting contributed to a significantly better response. In treatment with 0.5 or 0.2 MBq, the stabilized radioactive mAb significantly reduced tumor growth compared to the denatured immunoconjugate. Additionally, through a comparison between a stabilized 211At-anti-HER2 mAb and radioactive nontargeted control mAb, we demonstrate that active targeting significantly enhances tumor accumulation of radioactivity and in vivo antitumor effect. In RIT with 211At, active targeting contributes to efficient tumor accumulation of radioactivity, resulting in a potent antitumor effect. SA-dependent protection that successfully maintains tumor targeting will facilitate the clinical application of alpha-RIT.
Collapse
Affiliation(s)
- Hiroki Takashima
- Division
of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Kazunobu Ohnuki
- Division
of Functional Imaging, Exploratory Oncology
Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Shino Manabe
- Laboratory
of Functional Molecule Chemistry, Pharmaceutical Department and Institute
of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan,Research
Center for Pharmaceutical Development, Graduate School of Pharmaceutical
Sciences & Faculty of Pharmaceutical Sciences, Tohoku University, 6-3
Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan,Glycometabolic
Biochemistry Laboratory, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Yoshikatsu Koga
- Division
of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan,Department
of Strategic Programs, Exploratory Oncology
Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Ryo Tsumura
- Division
of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Takahiro Anzai
- Division
of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Yang Wang
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Xiaojie Yin
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Nozomi Sato
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Yudai Shigekawa
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Akihiro Nambu
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Sachiko Usuda
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Hiromitsu Haba
- Nishina
Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Hirofumi Fujii
- Division
of Functional Imaging, Exploratory Oncology
Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
| | - Masahiro Yasunaga
- Division
of Developmental Therapeutics, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan,Tel.: +81-4-7134-6857. Fax: +81-4-7134-6866.
| |
Collapse
|
8
|
Kaneda-Nakashima K, Shirakami Y, Watabe T, Ooe K, Yoshimura T, Toyoshima A, Wang Y, Haba H, Fukase K. Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter. Int J Mol Sci 2022; 23:ijms232415509. [PMID: 36555151 PMCID: PMC9779414 DOI: 10.3390/ijms232415509] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 10/29/2022] [Accepted: 12/02/2022] [Indexed: 12/13/2022] Open
Abstract
This study confirmed the effect of sodium/iodine symporter (NIS) expression on existing drugs by in vitro and in vivo tests using cultured cell lines. The tumor growth inhibitory effect of sodium astatide ([211At]NaAt) was evaluated by in vitro and in vivo tests using human thyroid cancer cells (K1, K1/NIS and K1/NIS-DOX). NIS expression in cancer cells was controlled using the Tet-On system. [131I]NaI was used as control existing drug. From the results of the in vitro studies, the mechanism of [211At]NaAt uptake into thyroid cancer cells is mediated by NIS, analogous to [131I]NaI, and the cellular uptake rate correlates with the expression level of NIS. [211At]NaAt's ability to inhibit colony formation was more than 10 times that of [131I]NaI per becquerel (Bq), and [211At]NaAt's DNA double-strand breaking (DSB) induction was more than ten times that of [131I]NaI per Bq, and [211At]NaAt was more than three times more cytotoxic than [131I]NaI (at 1000 kBq each). In vivo studies also showed that the tumor growth inhibitory effect of [211At]NaAt depended on NIS expression and was more than six times that of [131I]NaI per Bq.
Collapse
Affiliation(s)
- Kazuko Kaneda-Nakashima
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Correspondence: ; Tel.: +81-6-6850-8271
| | - Yoshifumi Shirakami
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Tadashi Watabe
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Suita, Osaka 565-0871, Japan
| | - Kazuhiro Ooe
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Takashi Yoshimura
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Atsushi Toyoshima
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa Wako, Saitama 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa Wako, Saitama 351-0198, Japan
| | - Koichi Fukase
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Toyonaka, Osaka 560-0043, Japan
| |
Collapse
|
9
|
Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J. Comparison of the Therapeutic Effects of [ 211At]NaAt and [ 131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model. Int J Mol Sci 2022; 23:ijms23169434. [PMID: 36012698 PMCID: PMC9409053 DOI: 10.3390/ijms23169434] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 08/09/2022] [Accepted: 08/18/2022] [Indexed: 12/11/2022] Open
Abstract
Astatine (211At) is an alpha-emitter with a better treatment efficacy against differentiated thyroid cancer compared with iodine (131I), a conventional beta-emitter. However, its therapeutic comparison has not been fully evaluated. In this study, we compared the therapeutic effect between [211At]NaAt and [131I]NaI. In vitro analysis of a double-stranded DNA break (DSB) and colony formation assay were performed using K1-NIS cells. The therapeutic effect was compared using K1-NIS xenograft mice administered with [211At]NaAt (0.4 MBq (n = 7), 0.8 MBq (n = 9), and 1.2 MBq (n = 4)), and [131I]NaI (1 MBq (n = 4), 3 MBq (n = 4), and 8 MBq (n = 4)). The [211At]NaAt induced higher numbers of DSBs and had a more reduced colony formation than [131I]NaI. In K1-NIS mice, dose-dependent therapeutic effects were observed in both [211At]NaAt and [131I]NaI. In [211At]NaAt, a stronger tumour-growth suppression was observed, while tumour regrowth was not observed until 18, 25, and 46 days after injection of 0.4, 0.8, and 1.2 MBq of [211At]NaAt, respectively. While in [131I]NaI, this was observed within 12 days after injection (1, 3, and 8 MBq). The superior therapeutic effect of [211At]NaAt suggests the promising clinical applicability of targeted alpha therapy using [211At]NaAt in patients with differentiated thyroid cancer refractory to standard [131I]NaI treatment.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Correspondence: ; Tel.: +81-6-6879-3461
| | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Osaka University Graduate School of Science, Suita 565-0871, Japan
| | - Tatsuhiko Sato
- Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Shirakata 2-4, Tokai 319-1195, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| | | | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Eku Shimosegawa
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Takashi Nakano
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan
| | - Jun Hatazawa
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| |
Collapse
|
10
|
Ukon N, Higashi T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, Nakamura Y. Manual on the proper use of meta-[ 211At] astato-benzylguanidine ([ 211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition). Ann Nucl Med 2022; 36:695-709. [PMID: 35794455 PMCID: PMC9304041 DOI: 10.1007/s12149-022-01765-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 05/24/2022] [Indexed: 11/26/2022]
Abstract
In this manuscript, we present the guideline for use of meta-[211At] astatobenzylguanidine ([211At] MABG), a newly introduced alpha emitting radiopharmaceutical to the up-coming World's first clinical trial for targeted alpha therapy (TAT) at Fukushima Medical University in Japan, focusing on radiation safety issues in Japan. This guideline was prepared based on a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on Oct. 5th, 2021. The study showed that patients receiving [211At] MABG do not need to be admitted to a radiotherapy room and that TAT using [211At] MABG is possible on an outpatient basis. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers or patient's family members. In this guideline, the following contents are also included: precautions for patients and their families, safety management associated with the use of [211At] MABG, education and training, and disposal of medical radioactive contaminants. TAT using [211At] MABG in Japan should be carried out according to this guideline. Although this guideline is based on the medical environment and laws and regulations in Japan, the issues for radiation protection and evaluation methodology presented in this guideline are useful and internationally acceptable as well.
Collapse
Affiliation(s)
- Naoyuki Ukon
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan
| | - Tatsuya Higashi
- Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1, Anagawa, Inage, Chiba, Chiba, 263-8555, Japan.
| | - Makoto Hosono
- Department of Radiology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan
| | - Seigo Kinuya
- Japanese Society of Nuclear Medicine, 3-1-17 Nishi-Azabu, Minato-ku, Tokyo, 106-0031, Japan
| | - Takahiro Yamada
- Atomic Energy Research Institute, Kindai University, Higashi-Osaka, 3-4-1 Kowakae, Osaka, 577-8502, Japan
| | - Sachiko Yanagida
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Masao Namba
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Yoshihide Nakamura
- Chiyoda Technol Corporation, 1-7-12 Yushima, Bunkyo-ku, Tokyo, 113-8681, Japan
| |
Collapse
|
11
|
Ma H, Li F, Shen G, Pan L, Liu W, Liang R, Lan T, Yang Y, Yang J, Liao J, Liu N. In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment. Bioorg Med Chem 2022; 55:116600. [PMID: 34999526 DOI: 10.1016/j.bmc.2021.116600] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/29/2021] [Accepted: 12/31/2021] [Indexed: 02/05/2023]
Abstract
Glioma is the most common primary intracranial tumor without effective treatment. Positron emission tomography tracers labeled with 68Ga targeting fibroblast activation protein (FAP) have shown favorable characteristics in the diagnosis of glioma. However, to the best of our knowledge, FAP-targeted endoradiotherapy has never been explored in glioma. Hence, in this study, we investigated the therapeutic effect of 211At-labeled fibroblast activation protein inhibitor (FAPI) for glioma in vitro and in vivo. By astatodestannylation reaction, we prepared 211At-FAPI-04 with a radiochemical yield of 45 ± 6.7% and radiochemical purity of 98%. With good stability in vitro, 211At-FAPI-04 showed fast and specific binding to FAP-positive U87MG cells, and could significantly reduce the cell viability, arrested cell cycle at G2/M phase and suppressed cell proliferative efficacy. Biodistribution studies revealed that 6-fold higher accumulation in tumor sites was achieved by intratumoral injection in comparison with intravenous injection. In U87MG xenografts, 211At-FAPI-04 obviously suppressed the tumor growth and prolonged the median survival in a dose-dependent manner without obvious toxicity to normal organs. In addition, reduced proliferation and increased apoptosis were also observed after 211At-FAPI-04 treatment. All these results suggest that targeted alpha-particle therapy (TAT) mediated by 211At-FAPI-04 can provide an effective and promising strategy for the treatment of glioma.
Collapse
Affiliation(s)
- Huan Ma
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Feize Li
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China.
| | - Guohua Shen
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Lili Pan
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Weihao Liu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Ranxi Liang
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Tu Lan
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Yuanyou Yang
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Jijun Yang
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Jiali Liao
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China
| | - Ning Liu
- Key Laboratory of Radiation Physics and Technology of the Ministry of Education; Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China.
| |
Collapse
|
12
|
Radiolabeling chemistry with heavy halogens iodine and astatine. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00013-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Watabe T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, Nakamura Y. Manual on the proper use of sodium astatide ([ 211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition). Ann Nucl Med 2021; 35:753-766. [PMID: 33978932 PMCID: PMC8197710 DOI: 10.1007/s12149-021-01619-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 04/20/2021] [Indexed: 11/17/2022]
Abstract
We present the guideline for use of [211At] sodium astatide (NaAt) for targeted alpha therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on 8th Feb, 2021. The study showed that patients receiving [211At]NaAt do not need to be admitted to a radiotherapy room and outpatient treatment is possible. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers. Precautions for patients and their families, safety management associated with the use of [211At]NaAt, education and training, and disposal of medical radioactive contaminants are also included in this guideline. Treatment using [211At]NaAt in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection and evaluation methodology shown here are considered internationally useful as well.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
| | - Makoto Hosono
- Department of Radiology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan
| | - Seigo Kinuya
- Japanese Society of Nuclear Medicine, 3-1-17 Nishi-Azabu, Minato-ku, Tokyo, 106-0031, Japan
| | - Takahiro Yamada
- Atomic Energy Research Institute, Kindai University, Higashi-Osaka, 3-4-1 Kowakae, Osaka, 577-8502, Japan
| | - Sachiko Yanagida
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Masao Namba
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Yoshihide Nakamura
- Chiyoda Technol Corporation, 1-7-12 Yushima, Bunkyo-ku, Tokyo, 113-8681, Japan
| |
Collapse
|
14
|
Watabe T, Kaneda-Nakashima K, Ooe K, Liu Y, Kurimoto K, Murai T, Shidahara Y, Okuma K, Takeuchi M, Nishide M, Toyoshima A, Shinohara A, Shirakami Y. Extended single-dose toxicity study of [ 211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer. Ann Nucl Med 2021; 35:702-718. [PMID: 33871803 PMCID: PMC8134311 DOI: 10.1007/s12149-021-01612-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 03/24/2021] [Indexed: 12/23/2022]
Abstract
OBJECTIVE Astatine (211At) is a promising alpha emitter as an alternative to iodine (131I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and Medical Devices Agency. Here, we performed an extended single-dose toxicity examination under a reliability standard, as a preclinical safety assessment of [211At]NaAt to determine the FIH dose. METHODS [211At]NaAt solution was injected into normal 6-week-old mice (male (n = 50) and female (n = 50), body weight: male 33.2 ± 1.7 g, female 27.3 ± 1.5 g), which were then divided into four groups: 5 MBq/kg (n = 20), 20 MBq/kg (n = 20), 50 MBq/kg (n = 30), saline control (n = 30). The mice were followed up for 5 days (primary evaluation point for acute toxicity: n = 80) or 14 days (n = 20: evaluation point for recovery) to monitor general condition and body weight change. At the end of the observation period, necropsy, blood test, organ weight measurement, and histopathological examination were performed. For body weight, blood test, and organ weight, statistical analyses were performed to compare data between the control and injected groups. RESULTS No abnormal findings were observed in the general condition of mice. In the 50 MBq/kg group, males (days 3 and 5) showed a significant decrease in body weight compared with the control. However, necropsy did not differ significantly beyond the range of spontaneous lesions. In the blood test, males (50 MBq/kg) and females (50 MBq/kg) showed a decrease in white blood cell and platelet counts on day 5, and recovery on day 14. In the testis, a considerable weight decrease was observed on day 14 (50 MBq/kg), and multinucleated giant cells were observed in all mice, indicating a significant change related to the administration of [211At]NaAt. CONCLUSIONS In the extended single-dose toxicity study of [211At]NaAt, administration of high doses resulted in weight loss, transient bone marrow suppression, and pathological changes in the testis, which require consideration in the FIH clinical trial.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Institute for Radiation Sciences, Osaka University, Suita, Japan.
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Suita, Japan
| | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kenta Kurimoto
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Takashi Murai
- Bioscience Business Division, KAC Co., Ltd, Kyoto, Japan
| | - Yuka Shidahara
- Bioscience Business Division, KAC Co., Ltd, Kyoto, Japan
| | - Kenji Okuma
- Bioscience Business Division, KAC Co., Ltd, Kyoto, Japan
| | | | | | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Toyonaka, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Japan
| | | |
Collapse
|
15
|
Kaneda-Nakashima K, Zhang Z, Manabe Y, Shimoyama A, Kabayama K, Watabe T, Kanai Y, Ooe K, Toyoshima A, Shirakami Y, Yoshimura T, Fukuda M, Hatazawa J, Nakano T, Fukase K, Shinohara A. α-Emitting cancer therapy using 211 At-AAMT targeting LAT1. Cancer Sci 2021; 112:1132-1140. [PMID: 33277750 PMCID: PMC7935802 DOI: 10.1111/cas.14761] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 11/27/2020] [Accepted: 12/01/2020] [Indexed: 12/28/2022] Open
Abstract
α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with 211 At-labeled α-methyl-l-tyrosine (211 At-AAMT) as a carrier of 211 At into tumors. 211 At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of 211 At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse 211 At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse 211 At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that 211 At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy.
Collapse
Affiliation(s)
- Kazuko Kaneda-Nakashima
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan
| | - ZiJian Zhang
- MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Yoshiyuki Manabe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Atsushi Shimoyama
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Kazuya Kabayama
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Tadashi Watabe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Yoshikatsu Kanai
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Bio-System Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Kazuhiro Ooe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan
| | - Yoshifumi Shirakami
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Takashi Yoshimura
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Mitsuhiro Fukuda
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| | - Jun Hatazawa
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Takashi Nakano
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| | - Koichi Fukase
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Atsushi Shinohara
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Radiochemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| |
Collapse
|
16
|
Hanaoka K, Miyaji N, Yoneyama H, Ogawa M, Maeda T, Sakaguchi K, Iimori T, Tsushima H. [Radiological Technology for Targeted Radionuclide Therapy]. Nihon Hoshasen Gijutsu Gakkai Zasshi 2020; 76:1237-1247. [PMID: 33342942 DOI: 10.6009/jjrt.2020_jsrt_76.12.1237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Targeted radioisotope therapy (TRT) is a radiotherapy using radioisotope or drug incorporating it and has been used as a treatment for selectively irradiating cancer cells. In recent years, interest in TRT has increased due to improvements in radionuclide production technology, development of new drugs and imaging modalities, and improvements in radiation technology. In order to enhance the effect of TRT, measurement of individual radiation doses to tumor tissue and organs at risk is important using highly quantitative nuclear medicine images. In this paper, we present a review of literature on optimization of TRT, which is a new research area from the perspective of radiation technology.
Collapse
Affiliation(s)
- Kohei Hanaoka
- Institute of Advanced Clinical Medicine, Kindai University
| | - Noriaki Miyaji
- Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research
| | - Hiroto Yoneyama
- Department of Radiological Technology, Kanazawa University Hospital
| | | | - Takamasa Maeda
- Radiological Technology Section, QST Hospital, National Institutes for Quantum and Radiological Science and Technology
| | | | | | - Hiroyuki Tsushima
- Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences
| |
Collapse
|
17
|
Nakanishi K, Yamamoto S, Watabe T, Kaneda‐Nakashima K, Shirakami Y, Ooe K, Toyoshima A, Shinohara A, Teramoto T, Hatazawa J, Kamada K, Yoshikawa A. Development of high‐resolution YAP(Ce) x‐ray camera for the imaging of astatine‐211(At‐211) in small animals. Med Phys 2020; 47:5739-5748. [DOI: 10.1002/mp.14455] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 08/02/2020] [Accepted: 08/07/2020] [Indexed: 01/28/2023] Open
Affiliation(s)
- Kouhei Nakanishi
- Department of Integrated Health Science Nagoya University Graduate School of Medicine Nagoya Japan
- Department of Radiology Akita Hospital Chiryu Japan
| | - Seiichi Yamamoto
- Department of Integrated Health Science Nagoya University Graduate School of Medicine Nagoya Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics Osaka University Graduate School of Medicine Suita Japan
| | | | | | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics Osaka University Graduate School of Medicine Suita Japan
| | | | - Atsushi Shinohara
- Department of Chemistry Graduate School of Science Osaka University Toyonaka Japan
| | | | - Jun Hatazawa
- Research Center for Nuclear Physics Osaka University Toyonaka Japan
| | - Kei Kamada
- New Industry Creation Hatchery Center (NICHe) Tohoku University Sendai Japan
| | - Akira Yoshikawa
- New Industry Creation Hatchery Center (NICHe) Tohoku University Sendai Japan
| |
Collapse
|